[New therapeutic approaches in glioblastomas]
Related Experiment Video
Updated: Aug 18, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
1Service de neurologie, Hôpital de la Salpêtrière, 57, bd de l'hopital, 75013 Paris. antoine.carpentier@psl.ap-hop-paris.fr
Abstract:
New therapeutic approaches based on the understanding of brain tumour biology are emerging. Signal transduction inhibitors (mainly targeted against the EGF receptor, the PI3K/Akt or the Ras/Raf pathways), proteases inhibitors and antiangiogenic agents are currently under investigations in clinical trials. The recent development of convection-enhanced delivery technique allows the administration of drugs which do not cross the blood-brain-barrier, such as selective toxins or immunostimulating oligonucleotides. This article reviews these emerging therapies currently under clinical trials in glioblastomas.
Insights
Emerging brain tumor therapies include signal transduction inhibitors, protease inhibitors, and antiangiogenic agents. Convection-enhanced delivery enables new treatments like toxins and oligonucleotides for glioblastomas in clinical trials.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Drug Development
Background:
- Brain tumor biology understanding is advancing therapeutic strategies.
- Glioblastomas remain a significant challenge requiring novel treatments.
Purpose of the Study:
- To review emerging therapeutic approaches for glioblastomas currently in clinical trials.
- To highlight novel drug delivery systems and targeted therapies.
Main Methods:
- Review of ongoing clinical trials for glioblastoma treatments.
- Analysis of signal transduction inhibitors, protease inhibitors, and antiangiogenic agents.
- Evaluation of convection-enhanced delivery for non-blood-brain-barrier-penetrating drugs.
Main Results:
- Signal transduction inhibitors targeting EGF receptor, PI3K/Akt, and Ras/Raf pathways are under investigation.
- Protease inhibitors and antiangiogenic agents are also in clinical trials.
- Convection-enhanced delivery facilitates administration of agents like selective toxins and immunostimulating oligonucleotides.
Conclusions:
- New therapeutic avenues are emerging for glioblastomas based on biological insights.
- Targeted therapies and advanced drug delivery systems show promise in clinical trials.
- Further research and clinical evaluation are crucial for these novel glioblastoma treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...